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individuals with familial FSGS, providing evidence for a subsetSpectrum of disease in familial focal and segmental glomerulo-
of families in which a genetic form is segregating. Each familysclerosis.
had at least one member with renal biopsy-confirmed FSGSBackground. Focal segmental glomerulosclerosis (FSGS) is
and at least one other member with either renal biopsy-con-the underlying pathologic entity in 5% of adults and 20% of
firmed FSGS or ESRD.children with end-stage renal disease (ESRD). FSGS is gener-
Results. Twenty-six families had individuals affected in moreally considered to be sporadic in origin.
than one generation [multigeneration (MG)], and the re-Methods. Recently, we identified 60 families involving 190
maining 34 families had only a single generation (SG) affected.
There was equal representation of males and females among
affected individuals. Ten percent of MG families were African
1The participating physicians in the Collaborative Research Group American, and 52% of SG families were African American.
were as follows:
The mean age of presentation was significantly higher in theNorth America:
MG families (32.5 6 14.6 years) compared with the SG familiesDr. Bill Bennett and Dr. Ahmed Alkhunaizi (Portland, OR, USA);
(20.1 6 12.1 years, P 5 0.0001). SG cases had higher levels ofDr. Darol Joseff (Santa Barbara, CA, USA); Dr. Mark Arons (Pine-
proteinuria at presentation (7.0 6 5.6 g/24 hr, compared withhurst, NC, USA); Dr. Restaino (Norfolk, VA, USA); Dr. John Foreman,
Dr. Delbert Wigfall, Dr. Steve Smith, and Dr. David Butterly (Durham, 3.8 6 3.4 g/24 hr, for the MG families, P 5 0.002). On renal
NC, USA); Dr. Uri Alon (Kansas City, MO, USA); Dr. Norman Wolfish biopsy, tubulointerstitial damage was more severe in patients
(Ottawa, Canada); Dr. Stanton Schultz (Evansville, IN, USA); Dr. in the SG families than in the MG families; however, the level
Jeffery Addison (Anniston, AL, USA); Dr. Pierre Faubert (Brooklyn, of glomerular damage did not differ between these groups.
NY, USA); Dr. Michael Freundlich (Margate, FL, USA); Dr. James Fifty percent of the patients had progressed to ESRD by theSmelser (Huntsville, AL, USA); Dr. David Warnock (Birmingham,
age of 30 years. Variables measured at presentation that wereAL, USA); Dr. Thomas Amato (Los Angeles, CA, USA); Dr. Paul
independently associated with poor renal survival were de-Grimm (Winnipeg, Canada); Dr. Jeffrey Harris (Winchester, VA, USA);
creased age, increased serum creatinine, and increased urinaryDr. Roger Rodby (Chicago, IL, USA); Dr. James Cain (Roanoke, VA,
USA); Dr. Dennis Geary (Toronto, Canada); Dr. Patrick Parfrey and protein excretion. Forty-one patients underwent successful re-
Ms. Donna Hefferton (Newfoundland, Canada). nal transplantation, with a 10-year graft survival rate of 62%.
Europe: One patient developed clinical and biopsy evidence of recur-
Professor Y. Pirson (Louvain, Belgium); Dr. Berbagui Hamid (Lyons, rence of FSGS in the allograft.
France); Dr. Paul Stevens (Canterbury, England, United Kingdom); Conclusion. These data confirm the existence of a non-Dr. Neemiye Tumer (Ankara, Turkey); Dr. Stephen Segerer (Munich,
Alport’s form of hereditary glomerulonephritis, which has aGermany); Dr. Rainer Valentin (Germany); Dr. Phil Kalra and Dr.
morphological pattern of FSGS.Nick Pritchard (Salford, England, United Kingdom); Dr. Vincent Bos-
teels and Dr. Louis Janssens (Kortrijk, Belgium); Dr. Kurt Vandepitte
(Lier, Belgium); Dr. Nick Plant (Newcastle, England, United Kingdom).
Other countries:
Focal segmental glomerulosclerosis (FSGS) is a pri-Dr. Kelvin Lynn and Dr. Ross Bailey (Christchurch, New Zealand);
Dr. Robert Walker (Dunedin, New Zealand); Dr. Grant Pidgeon (Wel- mary glomerular disease of unknown etiology with a popu-
lington, New Zealand); and Dr. Abdias Arestegui (Lima, Peru). lation incidence of approximately two per million [1–3].
FSGS is a major cause of end-stage renal failure, particu-Key words: glomerulonephritis, renal disease, genetics, FSGS, inher-
ited FSGS. larly in young people [4], accounts for at least 2.5% of
all cases of end-stage renal disease (ESRD), and it isReceived for publication November 13, 1998
refractory to treatment. It has been reported in patientsand in revised form April 7, 1999
Accepted for publication May 20, 1999 of varied ethnic backgrounds, including American Cau-
casian, European, Hispanic, and African American [5, 6], 1999 by the International Society of Nephrology
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although it appears to be more frequent among African a resting blood pressure of greater than 140/90 mm Hg.
All family history and clinical data were recorded in aAmericans than among other ethnic groups [6, 7]. The
etiology of FSGS is poorly understood: It is unclear database using the Pedigene system. As many first-de-
gree relatives as were available were studied for thewhether FSGS is the result of a systemic disease or an
intrinsic defect of the glomerulus [8–10]. presence of occult renal disease by the qualitative analy-
sis of a freshly voided urine specimen for proteinuria.Although it is well recognized that genetics plays an
important role in the development of many forms of Subjects who were demonstrated to have 21 or greater
proteinuria were invited to have a more completerenal disease [11–13], FSGS has, until recently, been
considered to be primarily a sporadic disorder. Recently, nephrological evaluation, including renal biopsy where
appropriate.we reported a number of families in which FSGS affected
multiple members within the same family (multiplex Within these families, subjects were classified as defi-
nitely affected, probably affected, status unknown, andFSGS families) [14]. The occurrence of FSGS in multiple
members of the same family has also been observed by probably unaffected.
Definitely affected. Subjects who had a renal biopsya number of other authors [15–26]. The identification of
large pedigrees with familial FSGS (FFSGS) may allow demonstrating FSGS in the absence of evidence for sec-
ondary FSGS were classified as definitely affected.the application of positional cloning technology to iden-
tify the underlying molecular pathogenesis of FSGS. We Probably affected. Family members with ESRD re-
quiring renal replacement therapy, who had not under-have recently developed an international collaborative
group to study this syndrome. Here we present our find- gone renal biopsy, or family members with 3 or 41 pro-
teinuria on a urine dipstick in the absence of otherings with respect to family history, clinical and associated
pathological findings, and their relationship to the long- systemic disease likely to lead to proteinuria (such as
diabetes or lupus) were classified as probably affected.term prognosis in this large series of multiplex FSGS
families. Status unknown. Family members with 1 or 21 pro-
teinuria or with 500 mg or less of proteinuria on a 24-
hour collection were classified as status unknown.
METHODS
Probably unaffected. Subjects within these families
Patients without evidence of proteinuria on dipstick urinalysis
were classified as probably unaffected.Families that contained at least two individuals who
carried a diagnosis of FSGS, as defined later in this arti- This report focuses on definitely affected or probably
affected individuals.cle, were ascertained. Sixty families were identified
through a variety of sources and referral patterns. Adver- Families were classified according to whether there
was evidence that individuals from one or more genera-tisements were placed in the leading nephrology journals
and on the “NEPHROL” e-mail nephrology discussion tions were affected. Families with multiple generations
(MG) affected had to have clear-cut evidence of verticalgroup. Cases were identified from the published litera-
ture. Information regarding additional patients was ob- transmission of the trait, with individuals from two or
more generations affected, based on the definitions giventained from the clinics and medical personnel in the
Division of Nephrology at Duke University Medical previously in this article. Families with single generation
(SG) involvement had no more than one generationCenter. In order to be included in this analysis, each
family needed to have at least one member with biopsy- demonstrating any manifestation of disease. This classi-
fication (SG) was applied only where the parents of theproven FSGS and either a second member with biopsy-
confirmed FSGS or other family members with ESRD. individuals were available for examination and/or urinal-
ysis and were demonstrated to be free of renal diseaseIndividuals were excluded if they had any secondary
form of FSGS such as those associated with HIV infec- or the parent died at an advanced age and was known
to have died of a nonrenal cause. Individuals whosetion, reflux nephropathy, sickle cell disease, or intrave-
nous drug use. parents were not available for examination or in whom
the cause of death was not available were excluded.A detailed family history was obtained from all partici-
pating families. Medical records and renal pathological
Pathological datamaterial were obtained when available to confirm the
diagnosis and family history reports. The medical records The histological diagnosis of FSGS was based on the
criteria of Churg, Habib, and White and required theof all of these subjects were reviewed to identify factors
pertaining to the clinical presentation of the disorder, presence of areas of glomerular sclerosis or tuft collapse
that were both focal (involving only a subpopulation ofassociated syndromes, natural history, pattern of inheri-
tance, and outcome following renal transplantation. Hy- glomeruli) and segmental [7]. Segmental hyalinosis was
present in several cases, but was not considered a require-pertension was considered to be present if at presentation
the subject was taking antihypertensive medication or had ment for the diagnosis. Morphological features considered
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ancillary factors supporting the diagnosis of FSGS in- 260 family members were examined and had urinalysis.
cluded the detection of focal, segmental glomerular These families were living in the United States (N 5
staining for immunoglobulin M and/or C3 by immuno- 33), the United Kingdom (N 5 5), Belgium (N 5 4),
fluorescence microscopy and the presence of epithelial New Zealand (N 5 4), France (N 5 3), Germany (N 5 1),
cell foot process effacement by electron microscopy. Turkey (N 5 1), Peru (N 5 6), and Canada (N 5 3).
Glomerular sclerotic lesions were further classified ac- One hundred and four subjects were considered to
cording to the presence or absence of “collapsing” fea- be definitely affected, and 86 were considered probably
tures [27, 28]. Glomerular lesions were considered to affected (vide supra). A total of eight family members
be of the collapsing variety if they had wrinkling and previously considered unaffected were identified as
“collapse” of the glomerular capillary walls with promi- probably affected as a result of screening for proteinuria.
nent hypertrophy and hyperplasia of the overlying vis- Twenty-six families had individuals affected from MG.
ceral epithelial cells, often accompanied by intracy- Figure 1 displays the pedigree of our largest family, in-
toplasmic protein resorption droplets. volving 37 affected individuals. In the remaining 34 fami-
In each case, possible underlying causes of segmental lies, only individuals from an SG were affected. The
glomerulonephritis (for example, immune complex de- transmission of the trait from both males and females
position, antiglomerular basement membrane antibod-
to both male and female children was observed, thusies, vasculitis) and other potential causes of segmental
excluding either a sex linkage or a mitochondrial DNAglomerular pathology (such as Alport’s syndrome) were
disorder.ruled out to the fullest extent possible on clinical and
Six families contained one set of twins each. Two ofhistological grounds.
these sets were dizygotic twins, and in each of theseRenal biopsies were performed and processed in a
families one member of the twin set was affected. Bothstandard fashion, and each was reviewed by an experi-
members of the twin set were affected in three of theenced renal pathologist (D.H.) without regard to clinical
four sets of monozygotic twins. In the one discordantinformation. Histological features were graded by calcu-
identical twin set, the affected was 11 years of age andlating the percentage of glomeruli exhibiting a particular
had 5 g of protein excretion with normal renal function.histological finding (global or segmental collapse or
Her father developed ESRD secondary to biopsy-provenglobal or segmental glomerulosclerosis) and by semi-
FSGS. The apparently unaffected child had been fol-quantitative analysis (using a scale of 0 to 31) for the
lowed for two years and had no protein excretion onfollowing features: visceral epithelial hypertrophy, mes-
dipstick.angial hypercellularity, synechiae, hyalinosis, tubular
microcysts, tubular epithelial degenerative and regenera- In only one family, the development of FFSGS was
tive changes, tubular atrophy, interstitial edema, intersti- associated with a dysmorphic syndrome. This was in two
tial inflammation, interstitial fibrosis, and arteriolar scle- children ages 22 months and 9 months who developed
rosis. These were recorded 0 for absent, 1 for ,20%, 2 FSGS with nephrotic syndrome. They were the children
for 20 to 50% and 3 for .50% of the biopsy surface from the marriage of first cousins, and had congenital
affected. microcephaly, hypotonia, poor neurological develop-
ment, and low-set ears in addition to nephrotic syn-Statistical analysis
drome.
Survival times were calculated as the time to initiation Clinical features at presentation were compared be-
of dialysis, renal transplantation, or death, whichever tween SG and MG cases. SG subjects presented at a
came first. In subjects not reaching ESRD, the date of younger age (20.1 6 12.1 vs. 32.5 6 14.6 years, P 5
last follow-up was taken as the date of censoring. 0.0001; Fig. 2), had heavier proteinuria (7.0 6 5.6 vs.
Kaplan–Meier product-limit survival times were calcu- 3.8 6 3.4 g/24 hr, P 5 0.002), and were more likely to
lated using SAS PROC LIFETEST (Cary, NC, USA). be hypertensive (82 vs. 60%, P 5 0.01) than individuals
Risk ratios were calculated using the Cox proportional
within MG families (Table 1). There was no differencehazards model, which was also used to test for the influ-
in serum creatinine between SG and MG individuals.ence of multiple risk factors on survival. The log rank
test was used to compare survival curves. Differences Pathologic features
between groups were assessed using the chi-square test
A total of 104 patients underwent renal biopsy, ofand Student’s t-test as appropriate. A P value of , 0.05
which 68 had electron microscopy and immunofluores-was considered significant.
cence examinations in addition to light microscopy. Re-
nal pathology slides were available for review by us from
RESULTS 88 biopsies performed on 75 patients, and the renal pa-
Clinical presentation thology reports were reviewed on the remainder. The
number of renal biopsies per family ranged from 1 toClinical and pathological data were available on 60
families involving 190 affected individuals. In addition, 15. Thirteen patients had two or more renal biopsies.
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Fig. 1. Pedigree of largest multigeneration family in the series. Symbols are: (j) affected male; (d) affected female; (h) unaffected male; (s) unaffected
female; (hu ) deceased.
Histological examination of biopsy tissue revealed a segmental sclerotic and collapsing lesions were seen in
biopsies from 15% of the patients. In all, 78% of thewide variety of glomerular and extraglomerular abnor-
malities. Segmental sclerosis was identified in biopsies patients had evidence of either segmental sclerosis or
collapse. The mean percentages of segmentally scleroticfrom 52% of patients with FFSGS, and segmental or
global collapse was seen in biopsies from 11%; both glomeruli and glomeruli with segmental and/or global
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Fig. 2. Age at presentation of patients with
familial focal segmental glomerulosclerosis
(FFSGS). Symbols are: (j) single generation
inheritance; (h) multigeneration inheritance.
Table 1. Clinical variables measured at presentation
Multigeneration Single generation
(N 5 125) (N 5 65) P
Race % black 10.1 52 0.001
Sex % male 44 43 0.5
Age at presentation years 32.5 6 14.6 20.1 6 12.1 0.0001
Serum Cr at presentation mg/dl 4.1 6 5.7 3.0 6 3.7 0.2
Proteinuria at presentation g/24 hr 3.8 6 3.4 7.0 6 5.6 0.002
Hypertension 60% 82% 0.01
Table 2. Histology of familial FSGS: Glomerular
Multigeneration Single generation P
Of all glomeruli
Global collapse % 2.5 6 5.7 12 6 22.1 0.07
Segmental collapse % 2.8 6 6.3 5.2 6 7.6 0.2
Global sclerosis % 19.7 6 21.9 27.2 6 33.4 0.4
Segmental sclerosis % 10.9 6 10.5 9 6 12.2 0.3
21 or greater on semiquantitative analysis
Visceral epithelial hypertrophy 9.3 5.8 0.1
Mesangial hypercellularity 0 0 NS
collapse did not differ significantly between SG and MG microcyst formation and interstitial edema were noted
in only a small fraction of the biopsies and did not differgroups (Table 2). Globally sclerotic glomeruli were a
common feature in both groups, constituting 19.7 6 significantly between the two groups. Extensive arterio-
lar sclerosis was seen in occasional biopsies, with approx-21.9% of the glomeruli in the MG biopsies and 27.2 6
33.4% in the SG group (P 5 0.4). imately equal frequency in the two groups.
In biopsies from 9% of patients, global glomerular
Renal survivalsclerosis was the only lesion identified. In half of these,
all of the glomeruli were globally sclerotic. In an addi- Ninety-three individuals developed ESRD. The me-
dian age for the development of ESRD was 30 years.tional 5% of biopsies, no significant glomerular lesions
were identified, possibly as a result of sampling early in Variables measured at the presentation that were sig-
nificantly associated with worse renal survival (Table 4)the course of the disease. The remaining 8% of biopsies
contained insufficient tissue for a definitive diagnosis. included decreased age of presentation, single-genera-
tion involvement (Fig. 3), increased serum creatinine,A variety of tubulointerstitial changes was also noted
in the biopsies (Table 3). Of particular note were tubular increased urinary protein excretion (Fig. 4), and black
race (Fig. 5). None of the pathological variables weredegeneration/regeneration, tubular atrophy, interstitial
inflammation, and interstitial fibrosis, all of which were significantly associated with prolonged renal survival.
Using backward elimination from the Cox proportionalsignificantly more prevalent in biopsies from the SG
group than those from the MG group. Prominent tubular hazards model (Table 5), the following variables were
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Table 3. Histology of familial FSGS: Tubulointerstitial
Multigeneration Single generation P
21 or greater on semiquantitative analysis
Tubular microcysts 0 2% 0.6
Tubular degeneration/regeneration 1% 9% 0.03
Tubular atrophy 3.6% 18% 0.002
Interstitial edema 0 5.3 0.9
Interstitial inflammation 3.1% 16.3% 0.004
Interstitial fibrosis 4.6% 17.8% 0.0039
Arteriolar sclerosis 6.1% 8.9% 0.3
Table 4. Clinical variables associated with progression to end-stage
renal disease (ESRD)
Risk ratio
(95% CI) P
Agea 0.66 (0.7–0.95) 0.0001
Creatinine 1.04 (1.02–1.07) 0.04
SG vs. MG 0.3 (0.2–0.4) 0.0001
Proteinuria 1.13 (1.1–1.16) 0.0001
Sex (male vs. female) (0.9–1.4) 0.4
Race (white vs. other) 2.1 (1.7–2.7) 0.0005
Hypertension (present vs. absent) (0.8–1.9) 0.4
Fig. 3. Survival based on the pattern of inheritance. Renal survivalAbbreviations are: SG, single generation; MG, multigeneration.
was worse in patients with single generation involvement (N 5 65)aRisk ratio expressed for 10 unit change.
compared with families with multigeneration involvement (N 5 125).
independently associated with worse renal survival:
younger age at presentation, increased serum creatinine,
and increased urinary protein excretion.
Outcome of renal transplantation
A total of 41 patients underwent 48 renal transplant
procedures. The 10-year survival of these grafts is out-
lined in Figure 6. At 10 years, 62% of grafts continued
to function. Only one patient demonstrated a recurrence
of FSGS in the allograft. Two subjects, who initially
appeared unaffected, donated a kidney to an affected
Fig. 4. Survival based on proteinuria at presentation. Renal survivalsibling and subsequently developed proteinuria and on was significantly worse in subjects who presented with greater than
renal biopsy were demonstrated to have FSGS [29]. Both 3 g of protein excretion per 24 hours (N 5 120) when compared with
those with lesser levels of protein excretion (N 5 70).of these individuals subsequently developed ESRD. The
recipient of one of these kidneys developed chronic allo-
graft rejection secondary to noncompliance with medica-
tions, and the other kidney functioned for greater than
pattern of inheritance. It is likely that MG families are10 years.
families with autosomal dominant inheritance and that
SG families have autosomal recessive inheritance, al-
DISCUSSION though there are also other possibilities, including au-
tosomal dominant with incomplete penetrance. We haveIn this report, we present a large series of patients
adopted a very conservative technique of labeling fami-with multiple family members affected with FFSGS. The
lies SG in that only families in which both parents werevertical mode of transmission in many of the families
examined and found to be free of renal disease wereand the development of FSGS in both sets of twins estab-
labeled SG. Families with SG involvement appear tolish this as a clearly genetic disorder, rather than the
have a more aggressive form of disease, as they presentedresult of some environmental exposure. We have ob-
at a younger age and with heavier proteinuria than MGserved the frequent development of ESRD in affected
families. It is possible that this apparently more aggres-individuals.
sive deterioration in renal function represents ascertain-In this review, we used the terms SG involvement and
MG involvement, as they make no assumptions about ment bias, in that individuals within families already
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family being affected by FSGS in the kidney in associa-
tion with other hereditary defects [15, 32–36]. Because
the disease is uncommon, the aggregation in a family of
more than one affected member is compelling evidence
for a major gene.
The weight of existing evidence in experimental mod-
els of FSGS and human sporadic FSGS supports a role
for a circulating factor that results in increased glomeru-
lar permeability [8, 9, 37, 38]. The early recurrence of
Fig. 5. Renal survival was significantly worse in African American FSGS after renal transplantation has been observed for
subjects when compared with Caucasians. more than 20 years and provides a tantalizing clue that a
circulating substance may be responsible for glomerular
injury in some patients with this entity. Further evidence
Table 5. Variables independently associated with progression for the presence of a circulating factor associated with
to ESRD FSGS is supported by the effectiveness of plasmapheresis
Risk ratio to treat recurrence of FSGS following renal transplanta-
(95% CI) P tion [9, 38]. However, unlike sporadic forms of FSGS,
Agea 0.46 (0.37–0.58) 0.007 we have observed the recurrence of FSGS in only one
Creatinine 1.2 (1.1–1.7) 0.01 of 41 renal transplant recipients with FFSGS, suggestingProteinuria 1.13 (1.1–1.5) 0.0002
that intrinsic abnormalities of the kidney are responsible
aExpressed for 10 unit change.
for FFSGS, rather than a circulating factor.
Not every subject in this study underwent a renal
biopsy to confirm the histological pattern of their glomer-
ular injury; however, most families did have at least two
individuals with a renal biopsy. In addition, not every
biopsy was subjected to electron microscopic and immu-
nofluorescence examination; however, at least one
biopsy from each family did undergo electron micros-
copy, excluding any changes of basement membrane
lamellation or splitting that would be compatible with
Alport’s-type nephropathy. A potential criticism of these
studies is the lack of histological confirmation in every
single affected individual, as many of the cases were
Fig. 6. Survival of renal allograft in patients with FFSGS.
classified as affected on the basis of the presence of
ESRD or proteinuria. However, in an analysis of our
largest pedigree, in which we have determined linkage
to chromosome 11, each affected individual carriedknown to be affected by renal disease are more likely
to be detected early. However, when the survival analysis the disease allele, and no unaffected individuals carried
it [39].was confined to the probands in each family, thus elimi-
nating the effect of ascertainment bias, the same trends Developments in molecular biology have enabled in-
vestigators to study genetic disorders by a “reverse genet-in terms of worse serum creatinine, higher proteinuria,
and earlier age of ESRD were apparent in the SG fami- ics approach” or “positional cloning” in which the ge-
netic disorder is initially linked to a chromosome marker.lies when compared with MG families.
The first reports of the occurrence of an autosomal Subsequently, mapping of the gene may be followed by
identification of the gene itself, the mutations responsibledominant FSGS came from Walker, Lynn, and Ross in
New Zealand in 1982 [24]. Walker et al reported seven for the disorder, and finally, the gene product. This ap-
proach is particularly suitable for a disorder such as thispatients in three families with familial FSGS that was
inherited as an autosomal dominant trait. Prior to this in which there is very little understanding of the underly-
ing pathophysiologic mechanisms responsible for the dis-report, there were a number of reports of non-Alport
hereditary nephropathy in which the renal pathology order. Recently, Mathis et al employed this approach in
studying a large kindred from Oklahoma (USA) [40].was incompletely described because of the absence of
electron microscopic and immunofluorescence examina- These investigators found strong evidence for linkage to
chromosome 19q. The clinical features of these patients,tions [30, 31]. There are now many reports of FFSGS in
diverse parts of the globe [15–26]. Also, there are a however, were very different than the patients in our
series, in that only a small minority of the patients innumber of reports of multiple members within the same
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Studies in animals and potential applications to humans. Lab InvestMathis et al’s study progressed to ESRD. The patients
73:596–605, 1995
in the Mathis study were also poorly characterized in 9. Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis
E, Lovell H, Warady B, Gunwar S, Chonko AM, Artero M,terms of renal pathology. We have also recently demon-
Vincenti F: Circulating factor associated with increased glomerularstrated linkage to chromosome 11q for our large New
permeability to albumin in recurrent focal segmental glomerulo-
Zealand family [39], confirming considerable genetic het- sclerosis. N Engl J Med 334:878–883, 1996
10. Ritz E: Pathogenesis of “idiopathic” nephrotic syndrome. N Englerogeneity in the molecular pathogenesis of FFSGS.
J Med 330:61–62, 1994The cases of FFSGS that we have described here ap-
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